During a recent event at Columbia University’s Irving Cancer Research Center, experts in hematologic oncology shared their insights on the latest trends in treating various blood cancers. They discussed exciting new therapies and research that aim to improve outcomes for leukemia, multiple myeloma, and lymphoma patients.
Dr. Nicole Lamanna, a leading expert in chronic lymphocytic leukemia (CLL), highlighted a significant development. The FDA recently approved a new treatment combination of acalabrutinib (Calquence) and venetoclax (Venclexta). Unlike standard chemotherapy, this fixed-duration approach could reshape how CLL is managed. Dr. Lamanna emphasized the need to weigh the benefits and risks of different drugs, including BTK and BCL-2 inhibitors, to make informed treatment choices.
Next, Dr. Rajshekhar Chakraborty focused on bispecific antibodies for multiple myeloma. He pointed out a major hurdle: many providers aren’t fully aware of how effective these antibodies can be in early treatments. He discussed the findings from the phase 3 MajesTEC-3 trial, which showed promising results for using teclistamab-cqyv (Tecvayli) alongside daratumumab (Darzalex Faspro). This combination is especially crucial for patients battling relapsed or refractory disease.
Lastly, Dr. Hua-Jay “Jeff” Cherng talked about translational research in lymphoma. He shared how new markers like ctDNA (circulating tumor DNA) and minimal residual disease could soon play a role in guiding patient treatment. He envisions a future where chemotherapy might be replaced with targeted therapies, especially for high-risk patients.
As blood cancer treatments evolve, staying informed about these advancements is key. The research being done is not just theoretical; it shows real promise in potentially improving patient care and outcomes.
For more details on the FDA’s approval of acalabrutinib and venetoclax, you can check out the full news release.
These insights reflect an exciting time in oncology, where innovation can lead to better lives for many patients.
